A Letter from the Desk of CBIH

2 weeks ago

HOUSTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings CEO Dante Picazo Addresses Cannabis Reclassification and DEA Hearings…

Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence

2 weeks ago

BNC210 improved PTSD symptom severity at Week 12 with efficacy observed as early as Week 4Company plans to initiate a…

Nature Methods Names Spatial Proteomics “Method of the Year 2024” — Akoya Biosciences Celebrates Industry Milestone

2 weeks ago

MARLBOROUGH, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, announced that…

Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform

2 weeks ago

CAMBRIDGE, United Kingdom, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune…

Evaxion announces 2025 milestones reflecting continued strong strategy execution

2 weeks ago

With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025The 2025 key milestones…

Major shareholder announcement – AIM International Mutual Funds

2 weeks ago

ANNOUNCEMENT NO. 287 9 December 2024 Major shareholder announcement Major shareholder announcement – AIM International Mutual Funds          Pursuant to…

Major shareholder announcement – Invesco Ltd.

2 weeks ago

ANNOUNCEMENT NO. 286 9 December 2024 Major shareholder announcement Major shareholder announcement – Invesco Ltd.          Pursuant to Section 30…

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

2 weeks ago

Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of…

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

2 weeks ago

Breakthrough Innovation for the Purification of mRNA Therapeutics and VaccinesWALTHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN),…

Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

2 weeks ago

No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant…